Mycobacterium tuberculosis: success through do

FEMS Microbiology Reviews
36, 514-532
DOI: 10.1111/j.1574-6976.2012.00331.x

Citation Report

#	Article	IF	Citations
1	The Role of Transport Mechanisms in Mycobacterium Tuberculosis Drug Resistance and Tolerance. Pharmaceuticals, 2012, 5, 1210-1235.	3.8	73
2	Healthcare-associated viral and bacterial infections in dentistry. Journal of Oral Microbiology, 2012, 4, 17659.	2.7	106
3	Molecular Biology of Drug Resistance in Mycobacterium tuberculosis. Current Topics in Microbiology and Immunology, 2012, 374, 53-80.	1.1	123
4	Detection and treatment of subclinical tuberculosis. Tuberculosis, 2012, 92, 447-452.	1.9	33
5	Tuberculosis vaccine development: strength lies in tenacity. Trends in Immunology, 2012, 33, 373-379.	6.8	67
6	Elimination of intracellularly residingMycobacterium tuberculosisthrough targeting of host and bacterial signaling mechanisms. Expert Review of Anti-Infective Therapy, 2012, 10, 1007-1022.	4.4	16
7	Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology, 2012, 23, 900-907.	6.6	68
8	Surviving the Macrophage: Tools and Tricks Employed by Mycobacterium tuberculosis. Current Topics in Microbiology and Immunology, 2012, 374, 189-209.	1.1	18
9	Exploring prospects of novel drugs for tuberculosis. Drug Design, Development and Therapy, 2012, 6, 217.	4.3	9
10	The Physical Stability of the Recombinant Tuberculosis Fusion Antigens H1 and H56. Journal of Pharmaceutical Sciences, 2013, 102, 3567-3578.	3.3	21
11	Resistance to environmental stresses byVibrio vulnificusin the viable but nonculturable state. FEMS Microbiology Ecology, 2013, 84, 213-222.	2.7	136
12	Structure-Guided Design of Novel Thiazolidine Inhibitors of O-Acetyl Serine Sulfhydrylase from Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2013, 56, 6457-6466.	6.4	46
13	Polyphosphate kinase 1, a central node in the stress response network of Mycobacterium tuberculosis, connects the two-component systems MprAB and SenX3â€“RegX3 and the extracytoplasmic function sigma factor, sigma E. Microbiology (United Kingdom), 2013, 159, 2074-2086.	1.8	44
14	Mycobacterial toxin MazF-mt6 inhibits translation through cleavage of 23S rRNA at the ribosomal A site. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8501-8506.	7.1	114
15	DormantMycobacterium tuberculosisFails To Block Phagosome Maturation and Shows Unexpected Capacity To Stimulate Specific Human T Lymphocytes. Journal of Immunology, 2013, 191, 274-282.	0.8	28
16	Innate Immunity and Its Regulation by Mast Cells. Journal of Immunology, 2013, 190, 4458-4463.	0.8	190
17	Tuberculosis: Current state of knowledge. Respirology, 2013, 18, 1047-1055.	2.3	14
18	Prospects for Tuberculosis Elimination. Annual Review of Public Health, 2013, 34, 271-286.	17.4	312

#	Article	IF	Citations
19	Mechanisms of microbial escape from phagocyte killing. Biochemical Society Transactions, 2013, 41, 475-490.	3.4	62
20	Structure of Ldt_{Mt2}, an<scp>L</scp>,<scp>D</scp>-transpeptidase fromMycobacterium tuberculosis. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 432-441.	2.5	36
21	Structural basis for the inhibition ofMycobacterium tuberculosis<scp>L</scp>,<scp>D</scp>-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 420-431.	2.5	68
22	Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out?. Cytokine and Growth Factor Reviews, 2013, 24, 335-343.	7.2	30
23	Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Medical Microbiology and Immunology, 2013, 202, 95-104.	4.8	63
24	The Mtb Proteome Library: A Resource of Assays to Quantify the Complete Proteome of Mycobacterium tuberculosis. Cell Host and Microbe, 2013, 13, 602-612.	11.0	165
25	Tuberculosis vaccines: Time to think about the next generation. Seminars in Immunology, 2013, 25, 172-181.	5.6	125
26	Improved Efficacy of Fosmidomycin against Plasmodium and Mycobacterium Species by Combination with the Cell-Penetrating Peptide Octaarginine. Antimicrobial Agents and Chemotherapy, 2013, 57, 4689-4698.	3.2	52
27	Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 1648-1653.	3.2	133
28	Activities of Drug Combinations against Mycobacterium tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions. Antimicrobial Agents and Chemotherapy, 2013, 57, 1428-1433.	3.2	61
29	Systems approach to tuberculosis vaccine development. Respirology, 2013, 18, 412-420.	2.3	26
30	Water Regime Influences Bulk Soil and Rhizosphere of Cereus jamacaru Bacterial Communities in the Brazilian Caatinga Biome. PLoS ONE, 2013, 8, e73606.	2.5	90
31	THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013070.	1.3	114
32	TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013072.	1.3	38
33	Management of Drug-Resistant TB. , 0, , .		1
34	Differential Macrophage Response to Slow- and Fast-Growing Pathogenic Mycobacteria. BioMed Research International, 2014, 2014, 1-10.	1.9	29
35	Non-Replicating Mycobacterium tuberculosis Elicits a Reduced Infectivity Profile with Corresponding Modifications to the Cell Wall and Extracellular Matrix. PLoS ONE, 2014, 9, e87329.	2.5	64
36	Mycobacteria Counteract a TLR-Mediated Nitrosative Defense Mechanism in a Zebrafish Infection Model. PLoS ONE, 2014, 9, e100928.	2.5	35

#	Article	IF	Citations
37	Evaluation of Propidium Monoazide Real-Time PCR for Early Detection of Viable Mycobacterium tuberculosis in Clinical Respiratory Specimens. Annals of Laboratory Medicine, 2014, 34, 203-209.	2.5	16
38	Systems-level modeling of mycobacterial metabolism for the identification of new (multi-)drug targets. Seminars in Immunology, 2014, 26, 610-622.	5.6	49
39	Transcriptional regulation of bacterial virulence gene expression by molecular oxygen and nitric oxide. Virulence, 2014, 5, 794-809.	4.4	90
40	23S rRNA as an a-Maz-ing new bacterial toxin target. RNA Biology, 2014, 11, 101-105.	3.1	13
41	The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Review of Vaccines, 2014, 13, 619-630.	4.4	62
42	The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics. Journal of rheumatology Supplement, The, 2014, 91, 11-16.	2.2	50
43	Macrophage-pathogen interactions in infectious diseases: new therapeutic insights from the zebrafish host model. DMM Disease Models and Mechanisms, 2014, 7, 785-797.	2.4	153
44	The importance of the viable but non-culturable state in human bacterial pathogens. Frontiers in Microbiology, 2014, 5, 258.	3.5	681
45	Reverse Translation in Tuberculosis: Neutrophils Provide Clues for Understanding Development of Active Disease. Frontiers in Immunology, 2014, 5, 36.	4.8	22
46	Succinate Dehydrogenase is the Regulator of Respiration in Mycobacterium tuberculosis. PLoS Pathogens, 2014, 10, e1004510.	4.7	87
47	Dietary Pyridoxine Controls Efficacy of Vitamin B ₆ -Auxotrophic Tuberculosis Vaccine Bacillus Calmette-GuÃ©rin Î" ureC :: hly Î" pdx1 in Mice. MBio, 2014, 5, e01262-14.	4.1	20
48	Global Adaptation to a Lipid Environment Triggers the Dormancy-Related Phenotype of Mycobacterium tuberculosis. MBio, 2014, 5, e01125-14.	4.1	102
49	Perspectives on host adaptation in response to Mycobacterium tuberculosis: Modulation of inflammation. Seminars in Immunology, 2014, 26, 533-542.	5.6	78
50	Introduction. Seminars in Immunology, 2014, 26, 429-430.	5.6	1
51	<scp>CarD</scp> integrates three functional modules to promote efficient transcription, antibiotic tolerance, and pathogenesis in mycobacteria. Molecular Microbiology, 2014, 93, 682-697.	2.5	31
52	Tuberculosis vaccine development at a divide. Current Opinion in Pulmonary Medicine, 2014, 20, 294-300.	2.6	35
53	A Caspase-Dependent Pathway Is Involved in Wnt/Î²-Catenin Signaling Promoted Apoptosis in Bacillus Calmette-Guerin Infected RAW264.7 Macrophages. International Journal of Molecular Sciences, 2014, 15, 5045-5062.	4.1	63
54	Replication ofMycobacterium Tuberculosisin Retinal Pigment Epithelium. JAMA Ophthalmology, 2014, 132, 724.	2.5	60

#	Article	IF	Citations
55	Ms1, a novel sRNA interacting with the RNA polymerase core in mycobacteria. Nucleic Acids Research, 2014, 42, 11763-11776.	14.5	32
57	Recent advances towards tuberculosis control: vaccines and biomarkers. Journal of Internal Medicine, 2014, 275, 467-480.	6.0	89
58	An RNA-seq method for defining endoribonuclease cleavage specificity identifies dual rRNA substrates for toxin MazF-mt3. Nature Communications, 2014, 5, 3538.	12.8	91
59	Progress in tuberculosis vaccine development and host-directed therapiesâ€"a state of the art review. Lancet Respiratory Medicine,the, 2014, 2, 301-320.	10.7	195
60	Tumor necrosis factor alpha in mycobacterial infection. Seminars in Immunology, 2014, 26, 203-209.	5.6	119
61	Aptamer Against Mannose-capped Lipoarabinomannan Inhibits Virulent Mycobacterium tuberculosis Infection in Mice and Rhesus Monkeys. Molecular Therapy, 2014, 22, 940-951.	8.2	60
62	Developmental biology ofStreptomycesfrom the perspective of 100 actinobacterial genome sequences. FEMS Microbiology Reviews, 2014, 38, 345-379.	8.6	120
63	Mycobacterium massiliense Induces Inflammatory Responses in Macrophages Through Toll-Like Receptor 2 and c-Jun N-Terminal Kinase. Journal of Clinical Immunology, 2014, 34, 212-223.	3.8	20
64	Structural analysis of MycobacteriumÂtuberculosis <scp>ATP</scp>â€binding cassette transporter subunit UgpB reveals specificity for glycerophosphocholine. FEBS Journal, 2014, 281, 331-341.	4.7	22
65	Critical research concepts in tuberculosis vaccine development. Clinical Microbiology and Infection, 2014, 20, 59-65.	6.0	24
66	Nanoparticle Encapsulated Lipopeptide Conjugate of Antitubercular Drug Isoniazid: In Vitro Intracellular Activity and in Vivo Efficacy in a Guinea Pig Model of Tuberculosis. Bioconjugate Chemistry, 2014, 25, 2260-2268.	3.6	44
67	Evaluation of DNA Primase DnaG as a Potential Target for Antibiotics. Antimicrobial Agents and Chemotherapy, 2014, 58, 1699-1706.	3.2	20
68	<scp>EspI</scp> regulates the <scp>ESX</scp>â€1 secretion system in response to <scp>ATP</scp> levels in <scp>M</scp>ycobacterium tuberculosis. Molecular Microbiology, 2014, 93, 1057-1065.	2.5	27
69	Detection of Mycobacterium tuberculosis in latently infected lungs by immunohistochemistry and confocal microscopy. Journal of Medical Microbiology, 2014, 63, 1432-1435.	1.8	19
70	Tuberculosis drug discovery in the postâ€postâ€genomic era. EMBO Molecular Medicine, 2014, 6, 158-168.	6.9	157
71	Interactions of isoniazid with membrane models: Implications for drug mechanism of action. Chemistry and Physics of Lipids, 2014, 183, 184-190.	3.2	19
72	Reactive dirty fragments: implications for tuberculosis drug discovery. Current Opinion in Microbiology, 2014, 21, 7-12.	5.1	28
73	Latent tuberculosis infection: What we know about its genetic control?. Tuberculosis, 2014, 94, 462-468.	1.9	34

#	Article	IF	Citations
74	Propionate represses the dnaA gene via the methylcitrate pathway-regulating transcription factor, PrpR, in Mycobacterium tuberculosis. Antonie Van Leeuwenhoek, 2014, 105, 951-959.	1.7	9
75	Association of Serum Levels of Iron, Copper, and Zinc, and Inflammatory Markers with Bacteriological Sputum Conversion During Tuberculosis Treatment. Biological Trace Element Research, 2014, 160, 176-184.	3.5	19
76	Growth Factor Receptor Bound Protein 2â€“Associated Binder 2, a Scaffolding Adaptor Protein, Negatively Regulates Host Immunity against Tuberculosis. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 575-585.	2.9	4
77	CysK2 from Mycobacterium tuberculosis Is an O -Phospho- <scp>l</scp> -Serine-Dependent S -Sulfocysteine Synthase. Journal of Bacteriology, 2014, 196, 3410-3420.	2.2	21
78	Environmental Dependence of Stationary-Phase Metabolism in Bacillus subtilis and Escherichia coli. Applied and Environmental Microbiology, 2014, 80, 2901-2909.	3.1	92
79	Beyond the IFN-Â horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. European Respiratory Journal, 2014, 43, 1472-1486.	6.7	135
80	Tuberculosis vaccines â€“ rethinking the current paradigm. Trends in Immunology, 2014, 35, 387-395.	6.8	109
81	Targeting Lipid Esterases in Mycobacteria Grown Under Different Physiological Conditions Using Activity-based Profiling with Tetrahydrolipstatin (THL). Molecular and Cellular Proteomics, 2014, 13, 435-448.	3.8	54
82	Novel Vaccination Strategies against Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a018523-a018523.	6.2	131
83	Mycobacterium tuberculosis in the Proteomics Era. Microbiology Spectrum, 2014, 2, .	3.0	16
84	Versatile myeloid cell subsets contribute to tuberculosisâ€associated inflammation. European Journal of Immunology, 2015, 45, 2191-2202.	2.9	63
85	Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface. Trials in Vaccinology, 2015, 4, 29-32.	1.2	1
86	Dynamic exometabolome analysis reveals active metabolic pathways in nonâ€replicating mycobacteria. Environmental Microbiology, 2015, 17, 4802-4815.	3.8	40
87	TOWARDS NEW ANTITUBERCULAR DRUGS. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2015, , .	0.0	0
88	The Non-Essential Mycolic Acid Biosynthesis Genes hadA and hadC Contribute to the Physiology and Fitness of Mycobacterium smegmatis. PLoS ONE, 2015, 10, e0145883.	2.5	22
89	Transcriptomics: the key to biomarker discovery during tuberculosis?. Biomarkers in Medicine, 2015, 9, 483-495.	1.4	12
90	Diagnosis and Management of Latent Tuberculosis Infection: Table 1.. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a017830.	6.2	52
91	Mycobacterium tuberculosis dormancy-associated antigen of Rv2660c induces stronger immune response in latent Mycobacterium tuberculosis infection than that in active tuberculosis in a Chinese population. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1103-1109.	2.9	18

#	Article	IF	Citations
92	A Novel Tuberculosis Antigen Identified from Human Tuberculosis Granulomas*. Molecular and Cellular Proteomics, 2015, 14, 1093-1103.	3.8	5
93	Succinylome Analysis Reveals the Involvement of Lysine Succinylation in Metabolism in Pathogenic Mycobacterium tuberculosis*. Molecular and Cellular Proteomics, 2015, 14, 796-811.	3.8	117
94	Latency-associated protein Rv2660c of Mycobacterium tuberculosis augments expression of proinflammatory cytokines in human macrophages by interacting with TLR2. Infectious Diseases, 2015, 47, 168-177.	2.8	16
95	Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment. Medical Microbiology and Immunology, 2015, 204, 647-656.	4.8	7
96	Coâ€evolution of <scp>M</scp>ycobacterium tuberculosis and <scp>H</scp>omo sapiens. Immunological Reviews, 2015, 264, 6-24.	6.0	244
97	Proteomic Analysis of Drug-Resistant Mycobacteria: Co-Evolution of Copper and INH Resistance. PLoS ONE, 2015, 10, e0127788.	2.5	6
98	Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis. Cell Host and Microbe, 2015, 18, 96-108.	11.0	229
99	Frequency of Mycobacterium tuberculosis-specific CD8+ T-cells in the course of anti-tuberculosis treatment. International Journal of Infectious Diseases, 2015, 32, 23-29.	3.3	20
100	The microbiome at the pulmonary alveolar niche and its role in Mycobacterium tuberculosis infection. Tuberculosis, 2015, 95, 651-658.	1.9	51
101	Biomembrane Organization and Function. Behavior Research Methods, 2015, 22, 65-96.	4.0	5
102	Characterization of Metabolically Quiescent Leishmania Parasites in Murine Lesions Using Heavy Water Labeling. PLoS Pathogens, 2015, 11, e1004683.	4.7	122
103	Innate and Adaptive Cellular Immune Responses toMycobacterium tuberculosisInfection. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a018424.	6.2	116
104	Profiling the Proteome of Mycobacterium tuberculosis during Dormancy and Reactivation. Molecular and Cellular Proteomics, 2015, 14, 2160-2176.	3.8	89
105	Biological Insights from a Simulation Model of the Critical FtsZ Accumulation Required for Prokaryotic Cell Division. Biochemistry, 2015, 54, 3803-3813.	2.5	6
106	Mycobacterium tuberculosis virulence: insights and impact on vaccine development. Future Microbiology, 2015, 10, 1177-1194.	2.0	18
107	Mycolyl arabino glycerols from synthetic mycolic acids. Tetrahedron Letters, 2015, 56, 3268-3272.	1.4	5
108	MicroRNA-125a Inhibits Autophagy Activation and Antimicrobial Responses during Mycobacterial Infection. Journal of Immunology, 2015, 194, 5355-5365.	0.8	132
109	Lipid droplet dynamics at early stages ofMycobacterium marinuminfection inDictyostelium. Cellular Microbiology, 2015, 17, 1332-1349.	2.1	76

#	Article	IF	Citations
111	Comprehensive insights into transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing. BMC Genomics, 2015, 16, 34.	2.8	90
112	Theories, Mechanisms and Patterns of Microbiome Species Coexistence in an Era of Climate Change. SpringerBriefs in Ecology, 2015, , 13-53.	0.2	11
113	Mycobacterial Nicotinate Mononucleotide Adenylyltransferase. Journal of Biological Chemistry, 2015, 290, 7693-7706.	3.4	25
114	Molecular signatures for vaccine development. Vaccine, 2015, 33, 5256-5261.	3.8	13
115	Challenging Mycobacterium tuberculosis dormancy mechanisms and their immunodiagnostic potential. Brazilian Journal of Infectious Diseases, 2015, 19, 636-642.	0.6	8
116	Differential Influence of Nutrient-Starved Mycobacterium tuberculosis on Adaptive Immunity Results in Progressive Tuberculosis Disease and Pathology. Infection and Immunity, 2015, 83, 4731-4739.	2.2	17
117	Evolution of Mycolic Acid Biosynthesis Genes and Their Regulation during Starvation in Mycobacterium tuberculosis. Journal of Bacteriology, 2015, 197, 3797-3811.	2.2	30
118	Structural basis of mapping the spontaneous mutations with 5-flurouracil in uracil phosphoribosyltransferase from Mycobacterium tuberculosis. Biochemical and Biophysical Research Communications, 2015, 467, 577-582.	2.1	7
119	Pupylation-dependent and -independent proteasomal degradation in mycobacteria. Biomolecular Concepts, 2015, 6, 285-301.	2.2	11
120	Macrophage-Inducible C-Type Lectin Mincle-Expressing Dendritic Cells Contribute to Control of Splenic Mycobacterium bovis BCG Infection in Mice. Infection and Immunity, 2015, 83, 184-196.	2.2	46
121	Inflammation and tuberculosis: hostâ€directed therapies. Journal of Internal Medicine, 2015, 277, 373-387.	6.0	103
122	T7 Phage Display Library a Promising Strategy to Detect Tuberculosis Specific Biomarkers. Mycobacterial Diseases: Tuberculosis & Leprosy, 2016, 6, .	0.1	7
123	microRNA-20a Inhibits Autophagic Process by Targeting ATG7 and ATG16L1 and Favors Mycobacterial Survival in Macrophage Cells. Frontiers in Cellular and Infection Microbiology, 2016, 6, 134.	3.9	71
124	A Dormant Microbial Component in the Development of Preeclampsia. Frontiers in Medicine, 2016, 3, 60.	2.6	64
125	Mass Spectrometry Offers Insight into the Role of Ser/Thr/Tyr Phosphorylation in the Mycobacteria. Frontiers in Microbiology, 2016, 7, 141.	3.5	26
126	Boromycin Kills Mycobacterial Persisters without Detectable Resistance. Frontiers in Microbiology, 2016, 7, 199.	3.5	67
127	The multiple stress responsive transcriptional regulator Rv3334 of Mycobacterium tuberculosis is an autorepressor and a positive regulator of kstR. FEBS Journal, 2016, 283, 3056-3071.	4.7	16
128	The emerging role of gasotransmitters in the pathogenesis of tuberculosis. Nitric Oxide - Biology and Chemistry, 2016, 59, 28-41.	2.7	29

#	Article	IF	Citations
129	Inhibitors of the Cysteine Synthase CysM with Antibacterial Potency against Dormant Mycobacterium tuberculosis. Journal of Medicinal Chemistry, 2016, 59, 6848-6859.	6.4	45
130	Changes in the Membrane-Associated Proteins of Exosomes Released from Human Macrophages after Mycobacterium tuberculosis Infection. Scientific Reports, 2016, 6, 37975.	3.3	51
131	Mycobacterium Lysine Îµ-aminotransferase is a novel alarmone metabolism related persister gene via dysregulating the intracellular amino acid level. Scientific Reports, 2016, 6, 19695.	3.3	31
132	EBP50 induces apoptosis in macrophages by upregulating nitric oxide production to eliminate intracellular Mycobacterium tuberculosis. Scientific Reports, 2016, 6, 18961.	3.3	9
133	Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. Future Microbiology, 2016, 11, 643-650.	2.0	36
134	EFIS lecture. Immune response to tuberculosis: How to control the most successful pathogen on earth. Immunology Letters, 2016, 175, 50-57.	2.5	8
135	Structure and mapping of spontaneous mutational sites of PyrR from Mycobacterium tuberculosis. Biochemical and Biophysical Research Communications, 2016, 471, 409-415.	2.1	5
136	Antibiotic resistance mechanisms in M. tuberculosis: an update. Archives of Toxicology, 2016, 90, 1585-1604.	4.2	177
137	Rv2074 is a novel F 420 H 2 â€dependent biliverdin reductase in Mycobacterium tuberculosis. Protein Science, 2016, 25, 1692-1709.	7.6	31
138	Emerging role of mesenchymal stem cells during tuberculosis: The fifth element in cell mediated immunity. Tuberculosis, 2016, 101, S45-S52.	1.9	19
139	Understanding the pathophysiology of the human TB lung granuloma usingin vitrogranuloma models. Future Microbiology, 2016, 11, 1073-1089.	2.0	13
140	8-Hydroxyquinolines Are Boosting Agents of Copper-Related Toxicity in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2016, 60, 5765-5776.	3.2	54
141	Mycobacterial WhiB6 Differentially Regulates ESX-1 and the Dos Regulon to Modulate Granuloma Formation and Virulence in Zebrafish. Cell Reports, 2016, 16, 2512-2524.	6.4	71
142	Hydrophobic Shielding Drives Catalysis of Hydride Transfer in a Family of F₄₂₀H₂-Dependent Enzymes. Biochemistry, 2016, 55, 6908-6918.	2.5	15
143	Artificial fluorogenic substrates in microfluidic devices for bacterial diagnostics in biotechnology. Journal of Flow Chemistry, 2016, 6, 3-7.	1.9	2
144	Human lysosomal acid lipase inhibitor lalistat impairs Mycobacterium tuberculosis growth by targeting bacterial hydrolases. MedChemComm, 2016, 7, 1797-1801.	3.4	18
145	Secretome profiling of highly virulent Mycobacterium bovis 04-303 strain reveals higher abundance of virulence-associated proteins. Microbial Pathogenesis, 2016, 100, 305-311.	2.9	17
146	Stochastic expression of a multiple antibiotic resistance activator confers transient resistance in single cells. Scientific Reports, 2016, 6, 19538.	3.3	85

#	Article	IF	Citations
147	Defining dormancy in mycobacterial disease. Tuberculosis, 2016, 99, 131-142.	1.9	66
148	Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. Tuberculosis, 2016, 97, 97-107.	1.9	7
149	Roles of Triolein and Lipolytic Protein in the Pathogenesis and Survival of Mycobacterium tuberculosis: a Novel Therapeutic Approach. Applied Biochemistry and Biotechnology, 2016, 178, 1377-1389.	2.9	7
150	Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions. Infection and Immunity, 2016, 84, 1650-1669.	2.2	48
151	Post-exposure vaccination with the vaccine candidate Bacillus Calmetteâ€“GuÃ©rin Î”ureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes and Infection, 2016, 18, 364-368.	1.9	19
152	Molecular Determinants in Phagocyte-Bacteria Interactions. Immunity, 2016, 44, 476-491.	14.3	190
153	In Vitro Investigation of Influences of Chitosan Nanoparticles on Fluorescein Permeation into Alveolar Macrophages. Pharmaceutical Research, 2016, 33, 1497-1508.	3.5	9
154	Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?. SpringerPlus, 2016, 5, 65.	1.2	22
155	Analyses of methyltransferases across the pathogenicity spectrum of different mycobacterial species point to an extremophile connection. Molecular BioSystems, 2016, 12, 1615-1625.	2.9	21
156	New insights into the survival mechanisms of rifampicin-resistantMycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 2016, 71, 655-660.	3.0	22
157	tRNA is a new target for cleavage by a MazF toxin. Nucleic Acids Research, 2016, 44, 1256-1270.	14.5	83
158	The Role of Mast Cells in Bacterial Infection. American Journal of Pathology, 2016, 186, 4-14.	3.8	82
159	Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Seminars in Immunopathology, 2016, 38, 153-166.	6.1	114
160	Binding and processing of Î²â€lactam antibiotics by the transpeptidase Ldt_{Mt2} from Mycobacterium tuberculosis. FEBS Journal, 2017, 284, 725-741.	4.7	35
161	Hypoxia Sensing and Persistence Genes Are Expressed during the Intragranulomatous Survival of Mycobacterium tuberculosis. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 637-647.	2.9	50
162	Assessment of Metabolic Changes in Mycobacterium smegmatis Wild-Type and alr Mutant Strains: Evidence of a New Pathway of <scp>d</scp>-Alanine Biosynthesis. Journal of Proteome Research, 2017, 16, 1270-1279.	3.7	12
163	Small Molecules That Sabotage Bacterial Virulence. Trends in Pharmacological Sciences, 2017, 38, 339-362.	8.7	111
164	Significant under expression of the DosR regulon in M.Âtuberculosis complex lineage 6 in sputum. Tuberculosis, 2017, 104, 58-64.	1.9	15

#	Article	IF	Citations
165	Epigenetic Phosphorylation Control of Mycobacterium tuberculosis Infection and Persistence. Microbiology Spectrum, 2017, 5, .	3.0	24
166	A Proteomic Signature of Dormancy in the Actinobacterium Micrococcus luteus. Journal of Bacteriology, 2017, 199, .	2.2	24
167	IL-10 down-regulates the expression of survival associated gene hspX of Mycobacterium tuberculosis in murine macrophage. Brazilian Journal of Infectious Diseases, 2017, 21, 386-390.	0.6	6
168	Rv3852 (H-NS) of Mycobacterium tuberculosis Is Not Involved in Nucleoid Compaction and Virulence Regulation. Journal of Bacteriology, 2017, 199, .	2.2	9
169	Selective Killing of Dormant Mycobacterium tuberculosis by Marine Natural Products. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	34
170	Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers. Expert Review of Vaccines, 2017, 16, 845-853.	4.4	11
171	Synthesis, biological evaluation, and molecular docking studies of novel 3â€arylâ€5â€(alkylâ€thio)â€1 Hâ€1,2,4â€triazoles derivatives targeting Mycobacterium tuberculosis Chemical Biology and Drug Design, 2017, 90, 1206-1214.	3.2	19
172	Characterization of an extracellular protein, Rv1076 from M. tuberculosis with a potential role in humoral response. International Journal of Biological Macromolecules, 2017, 101, 621-629.	7.5	13
173	MiR-23a-5p modulates mycobacterial survival and autophagy during mycobacterium tuberculosis infection through TLR2/MyD88/NF-ÎºB pathway by targeting TLR2. Experimental Cell Research, 2017, 354, 71-77.	2.6	80
174	Mycobacterium tuberculosis lysine-É›-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. Bioorganic and Medicinal Chemistry, 2017, 25, 2761-2771.	3.0	25
175	Multifaceted role of lipids inMycobacterium leprae. Future Microbiology, 2017, 12, 315-335.	2.0	24
176	Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	25
177	Inhibitors of Mycobacterium tuberculosis DosRST signaling and persistence. Nature Chemical Biology, 2017, 13, 218-225.	8.0	150
178	Cholesterol plays a larger role during Mycobacterium tuberculosis inÂvitro dormancy and reactivation than previously suspected. Tuberculosis, 2017, 103, 1-9.	1.9	31
179	Structural analyses of the MazEF4 toxin-antitoxin pair in Mycobacterium tuberculosis provide evidence for a unique extracellular death factor. Journal of Biological Chemistry, 2017, 292, 18832-18847.	3.4	25
180	New active leads for tuberculosis booster drugs by structure-based drug discovery. Organic and Biomolecular Chemistry, 2017, 15, 10245-10255.	2.8	22
181	The Alternative Sigma Factors SigE and SigB Are Involved in Tolerance and Persistence to Antitubercular Drugs. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	44
182	Calcimycin mediates mycobacterial killing by inducing intracellular calcium-regulated autophagy in a P2RX7 dependent manner. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 3190-3200.	2.4	28

#	Article	IF	Citations
183	Profiling of in vitro activities of urea-based inhibitors against cysteine synthases from Mycobacterium tuberculosis. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4582-4587.	2.2	13
184	Fitness-compensatory mutations facilitate the spread of drug-resistant F15/LAM4/KZN and F28 Mycobacterium tuberculosis strains in KwaZulu-Natal, South Africa. Journal of Genetics, 2017, 96, 599-612.	0.7	5
185	Tuberculosis Vaccines. , 2017, , 1-12.		0
186	Identification of mycobacterial bacterioferritin B for immune screening of tuberculosis and latent tuberculosis infection. Tuberculosis, 2017, 107, 119-125.	1.9	8
187	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific Reports, 2017, 7, 8853.	3.3	22
188	Role of long-chain acyl-CoAs in the regulation of mycolic acid biosynthesis in mycobacteria. Open Biology, 2017, 7, 170087.	3.6	14
189	BCG â€" old workhorse, new skills. Current Opinion in Immunology, 2017, 47, 8-16.	5.5	33
190	RNAâ€mediated signal perception in pathogenic bacteria. Wiley Interdisciplinary Reviews RNA, 2017, 8, e1429.	6.4	14
191	Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Scientific Reports, 2017, 7, 15010.	3.3	51
192	Genomics of Human Pulmonary Tuberculosis: from Genes to Pathways. Current Genetic Medicine Reports, 2017, 5, 149-166.	1.9	30
193	Novel approaches to tuberculosis vaccine development. International Journal of Infectious Diseases, 2017, 56, 263-267.	3.3	120
194	â€œGenetic regulation of Mycobacterium tuberculosis in a lipid-rich environmentâ€• Infection, Genetics and Evolution, 2017, 55, 392-402.	2.3	18
195	Preparation of the tri-arabino di-mycolate fragment of mycobacterial arabinogalactan from defined synthetic mycolic acids. Carbohydrate Research, 2017, 437, 36-42.	2.3	3
196	Epigenetic Phosphorylation Control ofMycobacterium tuberculosisInfection and Persistence. , 0, , 557-580.		1
197	Listeria monocytogenes switches from dissemination to persistence by adopting a vacuolar lifestyle in epithelial cells. PLoS Pathogens, 2017, 13, e1006734.	4.7	57
198	Modulation of Trehalose Dimycolate and Immune System by Rv0774c Protein Enhanced the Intracellular Survival of Mycobacterium smegmatis in Human Macrophages Cell Line. Frontiers in Cellular and Infection Microbiology, 2017, 7, 289.	3.9	28
199	Activation of the Wnt Pathway by Mycobacterium tuberculosis: A Wntâ€“Wnt Situation. Frontiers in Immunology, 2017, 8, 50.	4.8	51
200	Mycobacterial Dormancy Systems and Host Responses in Tuberculosis. Frontiers in Immunology, 2017, 8, 84.	4.8	105

#	Article	IF	Citations
201	What We Have Learned and What We Have Missed in Tuberculosis Pathophysiology for a New Vaccine Design: Searching for the â€œPink Swanâ€. Frontiers in Immunology, 2017, 8, 556.	4.8	29
202	Deletion of TGF-Î²1 Increases Bacterial Clearance by Cytotoxic T Cells in a Tuberculosis Granuloma Model. Frontiers in Immunology, 2017, 8, 1843.	4.8	39
203	New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria. Frontiers in Microbiology, 2017, 8, 681.	3.5	114
204	RNA Profiling Analysis of the Serum Exosomes Derived from Patients with Active and Latent Mycobacterium tuberculosis Infection. Frontiers in Microbiology, 2017, 8, 1051.	3.5	64
205	Human and Mouse Hematopoietic Stem Cells Are a Depot for Dormant Mycobacterium tuberculosis. PLoS ONE, 2017, 12, e0169119.	2.5	52
206	The transcriptional regulator LysG (Rv1985c) of Mycobacterium tuberculosis activates lysE (Rv1986) in a lysine-dependent manner. PLoS ONE, 2017, 12, e0186505.	2.5	6
207	Metabolic adaptation of two in silico mutants of Mycobacterium tuberculosis during infection. BMC Systems Biology, 2017, 11, 107.	3.0	27
208	Bacterial immunostat: Mycobacterium tuberculosis lipids and their role in the host immune response. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 9-18.	0.9	73
209	A Repeating Sulfated Galactan Motif Resuscitates Dormant Micrococcus luteus Bacteria. Applied and Environmental Microbiology, 2018, 84, .	3.1	3
210	No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. Biological Reviews, 2018, 93, 1518-1557.	10.4	92
211	Triacylglycerol: nourishing molecule in endurance of Mycobacterium tuberculosis. Journal of Biosciences, 2018, 43, 149-154.	1.1	7
212	On the intrinsic constraint of bacterial growth rate:M. tuberculosisâ€™s view of the protein translation capacity. Critical Reviews in Microbiology, 2018, 44, 455-464.	6.1	42
213	Mycobacterium tuberculosis Exploits a Molecular Off Switch of the Immune System for Intracellular Survival. Scientific Reports, 2018, 8, 661.	3.3	33
214	Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs. Redox Biology, 2018, 15, 452-466.	9.0	39
215	The structure of the Nâ€terminal module of the cell wall hydrolase RipA and its role in regulating catalytic activity. Proteins: Structure, Function and Bioinformatics, 2018, 86, 912-923.	2.6	26
216	System-wide coordinates of higher order functions in host-pathogen environment upon Mycobacterium tuberculosis infection. Scientific Reports, 2018, 8, 5079.	3.3	18
217	Microbial Offense vs Host Defense: Who Controls the TB Granuloma?. Veterinary Pathology, 2018, 55, 14-26.	1.7	24
218	The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box. Annual Review of Pharmacology and Toxicology, 2018, 58, 271-291.	9.4	43

#	Article	IF	Citations
219	Mycobacterial Membrane Proteins QcrB and AtpE: Roles in Energetics, Antibiotic Targets, and Associated Mechanisms of Resistance. Journal of Membrane Biology, 2018, 251, 105-117.	2.1	13
220	Aetiology of Persistent Endodontic Infections in Root-Filled Teeth. , 2018, , 21-32.		0
221	Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics, 2018, 36, 3434-3443.	3.5	21
222	Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery, 2018, 17, 35-56.	46.4	512
223	New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State. Clinical Microbiology Reviews, 2018, 31, .	13.6	55
224	Characterization of ML0314c of Mycobacterium leprae and deciphering its role in the immune response in leprosy patients. Gene, 2018, 643, 26-34.	2.2	20
225	Mycobacterium tuberculosis host cell interaction: Role of latency associated protein Acr-1 in differential modulation of macrophages. PLoS ONE, 2018, 13, e0206459.	2.5	5
226	EspL is essential for virulence and stabilizes EspE, EspF and EspH levels in Mycobacterium tuberculosis. PLoS Pathogens, 2018, 14, e1007491.	4.7	33
227	Associating H₂O₂₋and NO-related changes in the proteome of Mycobacterium smegmatis with enhanced survival in macrophage. Emerging Microbes and Infections, 2018, 7, 1-17.	6.5	13
228	Novel Acetamide Indirectly Targets Mycobacterial Transporter MmpL3 by Proton Motive Force Disruption. Frontiers in Microbiology, 2018, 9, 2960.	3.5	28
229	Vitamin D Levels in Active TB, Latent TB, Non-TB Pneumonia and Healthy Children: A Prospective Observational Study. Fetal and Pediatric Pathology, 2018, 37, 337-347.	0.7	16
230	Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. Journal of Infection, 2018, 77, 526-533.	3.3	30
231	Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells. Frontiers in Immunology, 2018, 9, 2127.	4.8	35
232	Macrophage-microbe interaction: lessons learned from the pathogen Mycobacterium tuberculosis. Seminars in Immunopathology, 2018, 40, 577-591.	6.1	46
233	A new model for chronic and reactivation tuberculosis: Infection with genetically attenuated Mycobacterium tuberculosis in mice with polar susceptibility. Tuberculosis, 2018, 113, 130-138.	1.9	8
234	Structural, functional and biological insights into the role ofMycobacterium tuberculosisVapBC11 toxinâ€“antitoxin system: targeting a tRNase to tackle mycobacterial adaptation. Nucleic Acids Research, 2018, 46, 11639-11655.	14.5	37
235	PE_PGRS3 ofMycobacterium tuberculosisis specifically expressed at low phosphate concentration, and its arginine-rich C-terminal domain mediates adhesion and persistence in host tissues when expressed inMycobacterium smegmatis. Cellular Microbiology, 2018, 20, e12952.	2.1	24
236	Viability, biofilm formation, and MazEF expression in drug-sensitive and drug-resistant Mycobacterium tuberculosis strains circulating in Xinjiang, China. Infection and Drug Resistance, 2018, Volume 11, 345-358.	2.7	7

#	Article	IF	Citations
237	Mycobacterium tuberculosis cording in alveolar macrophages of patients with pulmonary tuberculosis is likely associated with increased mycobacterial virulence. Tuberculosis, 2018, 112, 1-10.	1.9	18
238	Understanding the role of interactions between host and Mycobacterium tuberculosis under hypoxic condition: an in silico approach. BMC Genomics, 2018, 19, 555.	2.8	13
239	Modeling the Metabolic State of Mycobacterium tuberculosis Upon Infection. Frontiers in Cellular and Infection Microbiology, 2018, 8, 264.	3.9	19
240	Calcimycin induced IL-12 production inhibits intracellular mycobacterial growth by enhancing autophagy. Cytokine, 2018, 111, 1-12.	3.2	14
241	Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis. Frontiers in Microbiology, 2018, 9, 1367.	3.5	79
242	Globalization and Infectious Diseases. , 2018, , 123-137.		3
243	The Mycobacterial Membrane: A Novel Target Space for Anti-tubercular Drugs. Frontiers in Microbiology, 2018, 9, 1627.	3.5	40
244	From Phagocytes to Immune Defense: Roles for Coronin Proteins in Dictyostelium and Mammalian Immunity. Frontiers in Cellular and Infection Microbiology, 2018, 8, 77.	3.9	28
245	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clinical Microbiology Reviews, 2018, 31, .	13.6	353
246	Regulation of Three Virulence Strategies of Mycobacterium tuberculosis: A Success Story. International Journal of Molecular Sciences, 2018, 19, 347.	4.1	46
247	Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease. Chemotherapy, 2018, 63, 172-180.	1.6	75
248	Engineering microbes for targeted strikes against human pathogens. Cellular and Molecular Life Sciences, 2018, 75, 2719-2733.	5.4	24
249	Structural and functional insights into putative TAG accumulating hydrolase protein (Rv1179c) of Mycobacterium tuberculosis H37Rv. Gene Reports, 2018, 13, 66-71.	0.8	1
250	To Be Cytosolic or Vacuolar: The Double Life of Listeria monocytogenes. Frontiers in Cellular and Infection Microbiology, 2018, 8, 136.	3.9	37
251	The Physiology of Mycobacterium tuberculosis in the Context of Drug Resistance: A System Biology Perspective. , 2018, , .		3
252	Molecular Mechanisms of Drug Tolerance in Mycobacterium tuberculosis. Molecular Biology, 2018, 52, 372-384.	1.3	10
253	Elucidating the functional role of Mycobacterium smegmatis recX in stress response. Scientific Reports, 2019, 9, 10912.	3.3	6
254	The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis. Current Medicinal Chemistry, 2019, 26, 2051-2060.	2.4	14

#	Article	IF	Citations
255	A spectroelectrochemical investigation of the hemeâ€based sensor DevSÂfrom MycobacteriumÂtuberculosis: a redox versus oxygen sensor. FEBS Journal, 2019, 286, 4278-4293.	4.7	11
256	A journey through infectious risk associated with ruxolitinib. British Journal of Haematology, 2019, 187, 286-295.	2.5	28
257	Preexisting variation in DNA damage response predicts the fate of single mycobacteria under stress. EMBO Journal, 2019, 38, e101876.	7.8	27
258	Disrupting coupling within mycobacterial F-ATP synthases subunit Îµ causes dysregulated energy production and cell wall biosynthesis. Scientific Reports, 2019, 9, 16759.	3.3	29
259	A Convenient Synthetic Method to Improve Immunogenicity of Mycobacterium tuberculosis Related T-Cell Epitope Peptides. Vaccines, 2019, 7, 101.	4.4	6
260	Mycobacterium tuberculosis DosR regulon gene Rv2004c contributes to streptomycin resistance and intracellular survival. International Journal of Medical Microbiology, 2019, 309, 151353.	3.6	12
261	Carbon nanomaterials: a new way against tuberculosis. Expert Review of Medical Devices, 2019, 16, 863-875.	2.8	16
262	Application of model systems to study adaptive responses of Mycobacterium tuberculosis during infection and disease. Advances in Applied Microbiology, 2019, 108, 115-161.	2.4	4
263	Modeling of Mycobacterium tuberculosis dormancy in bacterial cultures. Tuberculosis, 2019, 117, 7-17.	1.9	15
264	IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. International Journal of Medical Microbiology, 2019, 309, 299-306.	3.6	14
265	Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 144.	3.9	21
266	Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model. Heliyon, 2019, 5, e01539.	3.2	6
267	Interactions of <scp>Pseudomonas aeruginosa</scp> with <scp>Acanthamoeba polyphaga</scp> Observed by Imaging Flow Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 555-564.	1.5	25
268	Comparative label-free lipidomic analysis of Mycobacterium tuberculosis during dormancy and reactivation. Scientific Reports, 2019, 9, 3660.	3.3	21
269	Genome-Wide Transcriptional Responses of Mycobacterium to Antibiotics. Frontiers in Microbiology, 2019, 10, 249.	3.5	53
270	Proteomic and transcriptomic experiments reveal an essential role of RNA degradosome complexes in shaping the transcriptome of Mycobacterium tuberculosis. Nucleic Acids Research, 2019, 47, 5892-5905.	14.5	50
271	Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase. ACS Chemical Biology, 2019, 14, 949-958.	3.4	15
272	Structural basis of hypoxic gene regulation by the Rv0081 transcription factor of MycobacteriumÂtuberculosis. FEBS Letters, 2019, 593, 982-995.	2.8	8

#	Article	IF	Citations
273	BCG Vaccination Prevents Reactivation of Latent Lymphatic Murine Tuberculosis Independently of CD4+ T Cells. Frontiers in Immunology, 2019, 10, 532.	4.8	14
274	Reactive species and pathogen antioxidant networks during phagocytosis. Journal of Experimental Medicine, 2019, 216, 501-516.	8.5	67
275	Assessment of 7 trace elements in serum of patients with nontuberculous mycobacterial lung disease. Journal of Trace Elements in Medicine and Biology, 2019, 53, 84-90.	3.0	18
276	Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy. AAPS PharmSciTech, 2019, 20, 120.	3.3	90
277	Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens. Frontiers in Immunology, 2019, 10, 89.	4.8	23
278	NapM enhances the survival of Mycobacterium tuberculosis under stress and in macrophages. Communications Biology, 2019, 2, 65.	4.4	11
279	Graphene oxide prevents mycobacteria entry into macrophages through extracellular entrapment. Nanoscale Advances, 2019, 1, 1421-1431.	4.6	28
280	A Carbonic Anhydrase Pseudogene Sensitizes Select Brucella Lineages to Low CO ₂ Tension. Journal of Bacteriology, 2019, 201, .	2.2	16
281	Quantitative analysis of Mycobacterium avium subsp. hominissuis proteome in response to antibiotics and during exposure to different environmental conditions. Clinical Proteomics, 2019, 16, 39.	2.1	23
282	Differential Culturability of Mycobacterium tuberculosis in Culture-Negative Sputum of Patients With Pulmonary Tuberculosis and in a Simulated Model of Dormancy. Frontiers in Microbiology, 2019, 10, 2381.	3.5	31
283	Tracking of quiescence in Leishmania by quantifying the expression of GFP in the ribosomal DNA locus. Scientific Reports, 2019, 9, 18951.	3.3	25
284	Reprogramming of Small Noncoding RNA Populations in Peripheral Blood Reveals Host Biomarkers for Latent and Active Mycobacterium tuberculosis Infection. MBio, 2019, 10, .	4.1	28
285	Can immunization with Bacillus Calmette-GuÃ©rin be improved for prevention or therapy and elimination of chronic Mycobacterium tuberculosis infection?. Expert Review of Vaccines, 2019, 18, 1219-1227.	4.4	5
286	iTRAQ-based quantitative proteomics reveals insights into metabolic and molecular responses of glucose-grown cells of Rubrivivax benzoatilyticus JA2. Journal of Proteomics, 2019, 194, 49-59.	2.4	15
287	Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines. Pharmaceutical Research, 2019, 36, 8.	3.5	20
288	Functional annotation of putative fadE9 of Mycobacterium tuberculosis as isobutyryl-CoA dehydrogenase involved in valine catabolism. International Journal of Biological Macromolecules, 2019, 122, 45-57.	7.5	6
289	Identifying Dormant Growth State of Mycobacteria by Orthogonal Analytical Approaches on a Single Cell and Ensemble Basis. Analytical Chemistry, 2019, 91, 881-887.	6.5	5
290	New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach. Journal of Proteomics, 2019, 192, 321-333.	2.4	30

#	Article	IF	Citations
291	Choroidal Tuberculoma Manifesting in A Patient of Eales Disease 6 Years after Initial Presentation. Ocular Immunology and Inflammation, 2020, 28, 100-102.	1.8	1
292	Recent updates on drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology, 2020, 128, 1547-1567.	3.1	190
293	Rv1273c, an ABC transporter of Mycobacterium tuberculosis promotes mycobacterial intracellular survival within macrophages via modulating the host cell immune response. International Journal of Biological Macromolecules, 2020, 142, 320-331.	7.5	7
294	Levels of miR-125a-5p are altered in Mycobacterium avium-infected macrophages and associate with the triggering of an autophagic response. Microbes and Infection, 2020, 22, 31-39.	1.9	19
295	Development of a Mucosal TB Vaccine Using Human Parainfluenza Type 2 Virus. , 2020, , 611-623.		0
296	Aryl Hydrocarbon Receptor Modulation by Tuberculosis Drugs Impairs Host Defense and Treatment Outcomes. Cell Host and Microbe, 2020, 27, 238-248.e7.	11.0	26
298	Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis. Frontiers in Immunology, 2020, 11, 557809.	4.8	10
299	Synthesis of Naphthoquinone Derivatives: Menaquinones, Lipoquinones and Other Vitamin K Derivatives. Molecules, 2020, 25, 4477.	3.8	14
300	Bioorthogonal Correlative Light-Electron Microscopy of Mycobacterium tuberculosis in Macrophages Reveals the Effect of Antituberculosis Drugs on Subcellular Bacterial Distribution. ACS Central Science, 2020, 6, 1997-2007.	11.3	15
301	A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers. Carbohydrate Polymers, 2020, 250, 116800.	10.2	73
303	Differentially culturable tubercle bacteria dynamics during standard anti-tuberculosis treatment: A prospective cohort study. Tuberculosis, 2020, 124, 101945.	1.9	5
304	Pangenome Analysis of Mycobacterium tuberculosis Reveals Core-Drug Targets and Screening of Promising Lead Compounds for Drug Discovery. Antibiotics, 2020, 9, 819.	3.7	15
305	Vaccines Against Tuberculosis: Problems and Prospects (Review). Applied Biochemistry and Microbiology, 2020, 56, 497-504.	0.9	6
306	Nitrate-nitrite fate and oxygen sensing in dormant Mycobacterium tuberculosis: A bioinorganic approach highlighting the importance of transition metals. Coordination Chemistry Reviews, 2020, 423, 213476.	18.8	8
307	Graphene Oxide-Linezolid Combination as Potential New Anti-Tuberculosis Treatment. Nanomaterials, 2020, 10, 1431.	4.1	20
308	Designing novel inhibitors against cyclopropane mycolic acid synthase 3 (PcaA): targeting dormant state of Mycobacterium tuberculosis. Journal of Biomolecular Structure and Dynamics, 2021, 39, 6339-6354.	3.5	4
309	PE_PGRS proteins ofMycobacterium tuberculosis: A specialized molecular task force at the forefront of hostâ€“pathogen interaction. Virulence, 2020, 11, 898-915.	4.4	32
310	The Neglected Microbial Components of Commercial Probiotic Formulations. Microorganisms, 2020, 8, 1177.	3.6	37

#	Article	IF	Citations
311	Regulatory role and mechanism of the inhibition of the Mcl-1 pathway during apoptosis and polarization of H37Rv-infected macrophages. Medicine (United States), 2020, 99, e22438.	1.0	5
312	Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy. Frontiers in Cellular and Infection Microbiology, 2020, 10, 443.	3.9	21
313	Enhanced tuberculosis clearance through the combination treatment with recombinant adenovirus-mediated granulysin delivery. Theranostics, 2020, 10, 10046-10056.	10.0	1
314	Mycobacterium tuberculosis Calcium Pump CtpF Modulates the Autophagosome in an mTOR-Dependent Manner. Frontiers in Cellular and Infection Microbiology, 2020, 10, 461.	3.9	13
315	The anti-tubercular activity of simvastatin is mediated by cholesterol-driven autophagy via the AMPK-mTORC1-TFEB axis. Journal of Lipid Research, 2020, 61, 1617-1628.	4.2	24
316	Regulation of mitogen-activated protein kinase signaling pathway and proinflammatory cytokines by ursolic acid in murine macrophages infected with Mycobacterium avium. Gastroenterology Insights, 2020, 12, 8717.	1.2	5
317	Methods for Detecting Mycobacterial Mixed Strain Infectionsâ€“A Systematic Review. Frontiers in Genetics, 2020, 11, 600692.	2.3	12
318	A Multi-Pronged Computational Pipeline for Prioritizing Drug Target Strategies for Latent Tuberculosis. Frontiers in Chemistry, 2020, 8, 593497.	3.6	9
319	Combining structure and genomics to understand antimicrobial resistance. Computational and Structural Biotechnology Journal, 2020, 18, 3377-3394.	4.1	17
320	Relevance of inducible nitric oxide synthase for immune control of Mycobacterium avium subspecies paratuberculosis infection in mice. Virulence, 2020, 11, 465-481.	4.4	3
321	Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments. Science Advances, 2020, 6, eaba4901.	10.3	33
322	Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis. Microbes and Infection, 2020, 22, 423-431.	1.9	9
323	Design of Polymeric Nanocapsules for Intranasal Vaccination against Mycobacterium Tuberculosis: Influence of the Polymeric Shell and Antigen Positioning. Pharmaceutics, 2020, 12, 489.	4.5	19
324	Residues of helix É‘2 are critical for catalytic efficiency of mycobacterial alkylhydroperoxide reductase subunit C. FEBS Letters, 2020, 594, 2829-2839.	2.8	0
325	Combination antituberculosis therapy: Opportunities and challenges to combat drug-resistant tuberculosis. , 2020, , 111-127.		0
326	Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. Frontiers in Immunology, 2020, 11, 316.	4.8	59
327	Tracking down the White Plague: The skeletal evidence of tuberculous meningitis in the Robert J. Terry Anatomical Skeletal Collection. PLoS ONE, 2020, 15, e0230418.	2.5	25
328	BCG and BCGÎ”BCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines. Npj Vaccines, 2020, 5, 21.	6.0	11

#	Article	IF	Citations
329	Formulation and evaluation of Î²-cyclodextrin-mediated inclusion complexes of isoniazid scaffolds: molecular docking and in vitro assessment of antitubercular properties. New Journal of Chemistry, 2020, 44, 4467-4477.	2.8	21
330	Comparative in-silico proteomic analysis discerns potential granuloma proteins of Yersinia pseudotuberculosis. Scientific Reports, 2020, 10, 3036.	3.3	4
331	TNF-Î± antagonists differentially induce TGF-Î²1-dependent resuscitation of dormant-like Mycobacterium tuberculosis. PLoS Pathogens, 2020, 16, e1008312.	4.7	25
332	Effects of hostâ€directed therapies on the pathology of tuberculosis. Journal of Pathology, 2020, 250, 636-646.	4.5	34
333	Inhibiting DosRST as a new approach to tuberculosis therapy. Future Medicinal Chemistry, 2020, 12, 457-467.	2.3	21
335	Metabolic profiling of dormant Mycolicibacterium smegmatis cellsâ€™ reactivation reveals a gradual assembly of metabolic processes. Metabolomics, 2020, 16, 24.	3.0	21
336	Strategic Moves of â€œSuperbugsâ€•Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges. ACS Pharmacology and Translational Science, 2020, 3, 373-400.	4.9	22
337	Human Alveolar and Splenic Macrophage Populations Display a Distinct Transcriptomic Response to Infection With Mycobacterium tuberculosis. Frontiers in Immunology, 2020, 11, 630.	4.8	10
338	Heterogeneous Strategies to Eliminate Intracellular Bacterial Pathogens. Frontiers in Microbiology, 2020, 11, 563.	3.5	22
339	Metalâ€based antimicrobial strategies against intramacrophageMycobacterium tuberculosis. Letters in Applied Microbiology, 2020, 71, 146-153.	2.2	11
340	The tuberculosis spectrum: Translating basic research into pediatric clinical practice. Medical Hypotheses, 2020, 141, 108091.	1.5	4
341	Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nature Nanotechnology, 2021, 16, 1-14.	31.5	150
342	Nanotechnologyâ€Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis. Advanced Therapeutics, 2021, 4, 2000113.	3.2	37
343	Phylogenetic and Biogeographic Patterns of Vibrio parahaemolyticus Strains from North America Inferred from Whole-Genome Sequence Data. Applied and Environmental Microbiology, 2021, 87, .	3.1	6
344	The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review. Antibiotics, 2021, 10, 91.	3.7	10
345	MoS2-based nanostructures for biomedical applications and carbon nanomaterials in TB treatment. , 2021, , 91-118.		1
346	Tuberculosis and pharmacological interactions: A narrative review. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100007.	3.6	11
347	Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner. Microorganisms, 2021, 9, 255.	3.6	13

#	Article	IF	Citations
348	Reduced ATP-dependent proteolysis of functional proteins during nutrient limitation speeds the return of microbes to a growth state. Science Signaling, 2021, 14, .	3.6	15
349	Survival of hypoxia-induced dormancy is not a common feature of all strains of the Mycobacterium tuberculosis complex. Scientific Reports, 2021, 11, 2628.	3.3	6
350	An Overview of Genetic Information of Latent Mycobacterium tuberculosis. Tuberculosis and Respiratory Diseases, 2021, 84, 1-12.	1.8	7
351	Studying Bacterial Persistence: Established Methods and Current Advances. Methods in Molecular Biology, 2021, 2357, 3-20.	0.9	2
352	PE_PGRS33, an Important Virulence Factor of Mycobacterium tuberculosis and Potential Target of Host Humoral Immune Response. Cells, 2021, 10, 161.	4.1	17
354	The adapter protein Myd88 plays an important role in limiting mycobacterial growth in a zebrafish model for tuberculosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 265-275.	2.8	5
355	Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy. Metabolites, 2021, 11, 88.	2.9	26
356	Roles for phthiocerol dimycocerosate lipids in Mycobacterium tuberculosis pathogenesis. Microbiology (United Kingdom), 2021, 167, .	1.8	17
358	Targeting endogenous gaseous signaling molecules as novel host-directed therapies against tuberculosis infection. Free Radical Research, 2021, 55, 655-670.	3.3	5
360	Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains. Journal of Medicinal Chemistry, 2021, 64, 4359-4395.	6.4	36
361	Antimicrobial Peptides as Potential Anti-Tubercular Leads: A Concise Review. Pharmaceuticals, 2021, 14, 323.	3.8	19
362	Genome-scale analyses of transcriptional start sites in Mycobacterium marinum under normoxic and hypoxic conditions. BMC Genomics, 2021, 22, 235.	2.8	3
363	Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies. Current Topics in Medicinal Chemistry, 2021, 21, 547-570.	2.1	14
364	The lipolytic activity of LipJ, a stress-induced enzyme, is regulated by its C-terminal adenylate cyclase domain. Future Microbiology, 2021, 16, 487-507.	2.0	5
365	Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiological Research, 2021, 246, 126674.	5.3	55
366	In vitro potency of 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione against drug-resistant and non-replicating persisters of Mycobacterium tuberculosis. Journal of Global Antimicrobial Resistance, 2021, 25, 202-208.	2.2	2
367	Cholesterol-dependent transcriptome remodeling reveals new insight into the contribution of cholesterol to Mycobacterium tuberculosis pathogenesis. Scientific Reports, 2021, 11, 12396.	3.3	23
368	In VitroProfiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0028221.	3.2	9

#	Article	IF	Citations
369	Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response. Infection and Immunity, 2021, 89, e0081220.	2.2	25
370	Proteome remodeling in the Mycobacterium tuberculosis PknG knockout: Molecular evidence for the role of this kinase in cell envelope biogenesis and hypoxia response. Journal of Proteomics, 2021, 244, 104276.	2.4	6
371	Role of Premycofactocin Synthase in Growth, Microaerophilic Adaptation, and Metabolism of Mycobacterium tuberculosis. MBio, 2021, 12, e0166521.	4.1	7
372	Recent Progress in Lyme Disease and Remaining Challenges. Frontiers in Medicine, 2021, 8, 666554.	2.6	55
373	Understanding Metabolic Remodeling in Mycobacterium smegmatis to Overcome Energy Exigency and Reductive Stress Under Energy-Compromised State. Frontiers in Microbiology, 2021, 12, 722229.	3.5	2
374	Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species. ACS Infectious Diseases, 2021, 7, 2876-2888.	3.8	2
375	Lipid transport across the mycobacterial cell envelope. IUCrJ, 2021, 8, 711-712.	2.2	1
376	A Perspective of Diverse Synthetic Approaches and Biological Applications of Vitamin K. Biochemistry, 0, , .	1.2	0
377	The Tuberculosis Vaccine Development Pipeline: Present and Future Priorities and Challenges for Research and Innovation. , 2021, , 395-405.		4
378	Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells. Frontiers in Immunology, 2020, 11, 594572.	4.8	11
379	Pathogens Hijack Host Cell Metabolism: Intracellular Infection as a Driver of the Warburg Effect in Cancer and Other Chronic Inflammatory Conditions. Immunometabolism, 2021, 3, .	1.6	13
380	Activity-Based Lipid Esterase Profiling of M. bovis BCG at Different Metabolic States Using Tetrahydrolipstatin (THL) as Bait. Methods in Molecular Biology, 2017, 1491, 75-85.	0.9	2
381	Hostâ€“Pathogen Interactions Influencing Mycobacterium tuberculosis Persistence and Drug Tolerance. , 2019, , 217-245.		1
382	Cell Wall Biosynthesis and Latency During Tuberculosis Infections. , 2019, , 1-21.		4
383	Interactions of Mycobacterium tuberculosis with Human Mesenchymal Stem Cells. , 2019, , 95-111.		3
384	Mycobacteria Infection and Lipid Droplets: Host and Pathogen Stealing, Sharing and Storing Fat. , 2019, , 201-229.		1
385	Infectious Lung Diseases and Endogenous Oxidative Stress. , 2019, , 125-148.		3
386	Nucleotide Excision Repair Pathway in Mycobacteria. , 2019, , 275-300.		2

#	Article	IF	Citations
387	Mesenchymal Stem Cells: A Hidden Arsenal for Mtb Persistence, Resuscitation, and Reactivation. , 2019, , 301-314.		2
388	The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis. Journal of Medicinal Chemistry, 2021, 64, 71-100.	6.4	32
389	Understanding cutaneous tuberculosis: two clinical cases. JMM Case Reports, 2016, 3, e005070.	1.3	9
390	Genome-wide characterization of monomeric transcriptional regulators in Mycobacterium tuberculosis. Microbiology (United Kingdom), 2016, 162, 889-897.	1.8	13
391	Diguanylate cyclase activity of the Mycobacterium leprae T cell antigen ML1419c. Microbiology (United) Tj ETQq0 0 0 rgBT /Overlock 10	1.8	8
392	Comparative proteomic profiles reveal characteristic Mycobacterium tuberculosis proteins induced by cholesterol during dormancy conditions. Microbiology (United Kingdom), 2017, 163, 1237-1247.	1.8	14
396	Blocking IL-10 receptor signaling ameliorates Mycobacterium tuberculosis infection during influenza-induced exacerbation. JCI Insight, 2019, 4, .	5.0	15
397	Dormancy in Cryptococcus neoformans: 60 years of accumulating evidence. Journal of Clinical Investigation, 2020, 130, 3353-3360.	8.2	35
398	CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. Journal of Clinical Investigation, 2014, 124, 1268-1282.	8.2	183
399	ESAT-6â€“dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo. Journal of Clinical Investigation, 2016, 126, 2109-2122.	8.2	52
400	Individuality, phenotypic differentiation, dormancy and â€˜persistenceâ€™ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research, 2015, 4, 179.	1.6	46
401	Individuality, phenotypic differentiation, dormancy and â€˜persistenceâ€™ in culturable bacterial systems: commonalities shared by environmental, laboratory, and clinical microbiology. F1000Research, 2015, 4, 179.	1.6	49
402	The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB. PLoS Computational Biology, 2016, 12, e1004749.	3.2	21
403	Non-Invasive Microbial Metabolic Activity Sensing at Single Cell Level by Perfusion of Calcein Acetoxymethyl Ester. PLoS ONE, 2015, 10, e0141768.	2.5	17
404	PE_PGRS33 Contributes to Mycobacterium tuberculosis Entry in Macrophages through Interaction with TLR2. PLoS ONE, 2016, 11, e0150800.	2.5	62
405	A Mouse Model of Latent Tuberculosis Infection to Study Intervention Strategies to Prevent Reactivation. PLoS ONE, 2016, 11, e0158849.	2.5	26
406	Childhood tuberculosis is associated with decreased abundance of T cell gene transcripts and impaired T cell function. PLoS ONE, 2017, 12, e0185973.	2.5	15
408	PPE26 induces TLR2-dependent activation of macrophages and drives Th1-type T-cell immunity by triggering the cross-talk of multiple pathways involved in the host response. Oncotarget, 2015, 6, 38517-38537.	1.8	39

#	Article	IF	Citations
409	Mycobacterium tuberculosis Treatment Modalities and Recent Insights. Current Drug Delivery, 2014, 11, 744-752.	1.6	10
410	New Targets and Inhibitors of Mycobacterial Sulfur Metabolism. Infectious Disorders - Drug Targets, 2013, 13, 85-115.	0.8	40
411	The Influence of Pyrazinamide Monoresistance on Treatment Outcomes in Tuberculosis Patients from Southern China. Journal of Tuberculosis Research, 2016, 04, 9-17.	0.2	4
412	Novel concepts in the epidemiology, diagnosis and prevention of childhood tuberculosis. Swiss Medical Weekly, 2014, 144, w14000.	1.6	28
413	Understanding the early host immune response against Mycobacterium tuberculosis. Central-European Journal of Immunology, 2020, 45, 99-103.	1.2	13
414	Construction of a DNA Vaccine Encoding Mtb32C and HBHA Genes of Mycobacterium tuberculosis. Jundishapur Journal of Microbiology, 2015, 8, e21556.	0.5	14
415	Lipid droplets and the transcriptome of Mycobacterium tuberculosis from direct sputa: a literature review. Lipids in Health and Disease, 2021, 20, 129.	3.0	10
416	Mechanism-Based Inactivation of Mycobacterium tuberculosis Isocitrate Lyase 1 by (2R,3S)-2-Hydroxy-3-(nitromethyl)succinic acid. Journal of the American Chemical Society, 2021, 143, 17666-17676.	13.7	4
417	Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success. Frontiers in Microbiology, 2021, 12, 750124.	3.5	30
418	Mycobacterium tuberculosis in the Proteomics Era. , 0, , 239-260.		0
419	Perbedaan Antara Jumlah Sel T Subset Gamma-Delta di Darah Tepi pada Penderita Tuberkulosis dan Orang dengan Latent Tuberculosis Infection. Jurnal Biosains Pascasarjana, 2016, 18, 162.	0.2	0
420	MicroRNA AND TUBERCULOSIS. Russian Journal of Infection and Immunity, 2018, 8, 309-315.	0.7	2
422	Nutrient Depletion and Bacterial Persistence. , 2019, , 99-132.		3
425	Dispersion et dÃ©mographie de Mycobacterium tuberculosis dans un contexte de globalisation. , 2019, , 41-49.		0
427	Immune Correlates of Non-Necrotic and Necrotic Granulomas in Pulmonary Tuberculosis: A Pilot Study. Journal of Respiration, 2021, 1, 248-259.	1.1	5
428	Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches. Frontiers in Immunology, 2021, 12, 762315.	4.8	7
429	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 51-62.		0
430	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 1-12.		0

#	Article	IF	Citations
431	Generating Three-dimensional Human Granulomas in vitro to Study Mycobacterium tuberculosis-Host Interaction. Bio-protocol, 2020, 10, e3820.	0.4	0
432	Prevalence of Infection with Nocardia seriolae in Juvenile of Yellowtail Seriola quinqueradiata Cultured in Owase Bay, Japan. Fish Pathology, 2020, 55, 1-7.	0.7	4
434	A new in vitro dormancy model of <i>Mycobacterium tuberculosis</i>. Tuberculosis and Lung Diseases, 2020, 98, 19-26.	0.7	0
436	Genome-wide SNP and InDel mutations in Mycobacterium tuberculosis associated with rifampicin and isoniazid resistance. International Journal of Clinical and Experimental Pathology, 2018, 11, 3903-3914.	0.5	1
437	Novel Assay Platform to Evaluate Intracellular Killing of Mycobacterium tuberculosis: In Vitro and In Vivo Validation. Frontiers in Immunology, 2021, 12, 750496.	4.8	10
438	Mycobacterium tuberculosis latency-associated antigen Rv1733c SLP improves the accuracy of differential diagnosis of active tuberculosis and latent tuberculosis infection. Chinese Medical Journal, 2022, 135, 63-69.	2.3	2
439	Host-Microbial Relationship: Immune Response to Microbial Infections with or without Medication. , 0, , .		0
441	Mycobacterial MCE proteins as transporters that control lipid homeostasis of the cell wall. Tuberculosis, 2022, 132, 102162.	1.9	14
442	Delamanid or pretomanid? A Solomonic judgement!. Journal of Antimicrobial Chemotherapy, 2022, 77, 880-902.	3.0	21
443	Clp protease and antisense RNA jointly regulate the global regulator CarD to mediate mycobacterial starvation response. ELife, 2022, 11, .	6.0	6
444	Current Methods and Role of Next-Generation Sequencing in the Diagnosis of Antimicrobial Resistance in Tuberculosis. Clinical Microbiology Newsletter, 2022, 44, 1-12.	0.7	3
445	The Role of Fatty Acid Metabolism in Drug Tolerance of Mycobacterium tuberculosis. MBio, 2022, 13, e0355921.	4.1	16
446	Triacylglycerol: nourishing molecule in endurance of Mycobacterium tuberculosis. Journal of Biosciences, 2018, 43, 149-154.	1.1	2
447	Mesenchymal Stem Cells: Potential Role against Bacterial Infection. Journal of Biosciences and Medicines, 2022, 10, 97-113.	0.2	2
448	Photoclick Reaction Constructs Glutathione-Responsive Theranostic System for Anti-Tuberculosis. Frontiers in Molecular Biosciences, 2022, 9, 845179.	3.5	26
449	The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic. Frontiers in Immunology, 2022, 13, 833715.	4.8	7
450	A Feedback Regulatory Loop Containing McdR and WhiB2 Controls Cell Division and DNA Repair in Mycobacteria. MBio, 2022, 13, e0334321.	4.1	5
451	The Biological and Clinical Aspects of a Latent Tuberculosis Infection. Tropical Medicine and Infectious Disease, 2022, 7, 48.	2.3	10

#	Article	IF	Citations
452	The Viable But Non-Culturable State of Listeria monocytogenes in the One-Health Continuum. Frontiers in Cellular and Infection Microbiology, 2022, 12, 849915.	3.9	7
453	AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN. Indian Drugs, 2022, 59, 7-22.	0.1	0
455	Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0158821.	3.2	2
456	Reprogramming Mycobacterium tuberculosis CRISPR System for Gene Editing and Genome-wide RNA Interference Screening. Genomics, Proteomics and Bioinformatics, 2022, 20, 1180-1196.	6.9	7
457	Postbiotics as the new frontier in food and pharmaceutical research. Critical Reviews in Food Science and Nutrition, 2023, 63, 8375-8402.	10.3	41
458	Data Mining for ICD-10 Admission Diagnoses Preceding Tuberculosis within 1 Year among Non-HIV and Non-Diabetes Patients. Tropical Medicine and Infectious Disease, 2022, 7, 61.	2.3	1
485	Game theory applications in host-microbe interactions toward disease manifestation: infection as an example.. Iranian Journal of Basic Medical Sciences, 2021, 24, 1324-1335.	1.0	1
486	Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation. Pharmaceuticals, 2022, 15, 560.	3.8	3
487	Negative pressure promotes macrophage M1 polarization after Mycobacterium tuberculosis infection via the lncRNA XIST/microRNAâ€“125bâ€“5p/A20/NFâ€“ÎºB axis. Annals of the New York Academy of Sciences, 2022, 1514, 116-131.	3.8	8
489	Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages. Vaccines, 2022, 10, 831.	4.4	5
490	A review on enzyme complexes of electron transport chain from Mycobacterium tuberculosis as promising drug targets. International Journal of Biological Macromolecules, 2022, 212, 474-494.	7.5	8
491	Identifying RO9021 as a Potential Inhibitor of PknG fromMycobacterium tuberculosis: Combinative Computational and In Vitro Studies. ACS Omega, 2022, 7, 20204-20218.	3.5	2
492	Uncovering the Mast Cell Response to Mycobacterium tuberculosis. Frontiers in Immunology, 2022, 13, .	4.8	1
493	The Peripherally Membrane-Attached Protein MbFACL6 of Mycobacterium Tuberculosis Activates a Broad Spectrum of Substrates. SSRN Electronic Journal, 0, , .	0.4	0
494	Nucleic Acids Detection for Mycobacterium tuberculosis Based on Gold Nanoparticles Counting and Rolling-Circle Amplification. Biosensors, 2022, 12, 448.	4.7	4
495	Klf10 favorsMycobacterium tuberculosissurvival by impairing IFN-Î³ production and preventing macrophages reprograming to macropinocytosis. Journal of Leukocyte Biology, 2022, 112, 475-490.	3.3	2
496	S -Adenosylmethionineâ€“responsive cystathionine Î²-synthase modulates sulfur metabolism and redox balance in Mycobacterium tuberculosis. Science Advances, 2022, 8, .	10.3	10
497	Controlled Human Infection Models To Accelerate Vaccine Development. Clinical Microbiology Reviews, 2022, 35, .	13.6	12

#	Article	IF	Citations
499	Commonalities of Mycobacterium tuberculosis Transcriptomes in Response to Defined Persisting Macrophage Stresses. Frontiers in Immunology, 0, 13, .	4.8	7
500	Increased Heme Oxygenase 1 Expression upon a Primary Exposure to the Respiratory Syncytial Virus and a Secondary Mycobacterium bovis Infection. Antioxidants, 2022, 11, 1453.	5.1	3
501	Maternal serum zinc level is associated with risk of preeclampsia: A systematic review and meta-analysis. Frontiers in Public Health, 0, 10, .	2.7	12
502	Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	4
503	Comprehensive lipid and lipid-related gene investigations of host immune responses to characterize metabolism-centric biomarkers for pulmonary tuberculosis. Scientific Reports, 2022, 12, .	3.3	11
504	Prediction of Th1 and Cytotoxic T Lymphocyte Epitopes of Mycobacterium tuberculosis and Evaluation of Their Potential in the Diagnosis of Tuberculosis in a Mouse Model and in Humans. Microbiology Spectrum, 2022, 10, .	3.0	4
505	Manipulation and exploitation of host immune system by pathogenicMycobacterium tuberculosisfor its advantage. Future Microbiology, 2022, 17, 1171-1198.	2.0	5
507	Immuno-modulatory Drugs: a Rapid Way to Combat the Tuberculosis. Medicine in Omics, 2022, , 100016.	1.3	0
508	Evidence, Challenges, and Knowledge Gaps Regarding Latent Tuberculosis in Animals. Microorganisms, 2022, 10, 1845.	3.6	3
509	The Peripherally Membrane-attached Protein MbFACL6 of Mycobacterium tuberculosis Activates a Broad Spectrum of Substrates. Journal of Molecular Biology, 2022, 434, 167842.	4.2	0
510	Mycobacterial acyl carrier protein suppresses TFEB activation and upregulates miR-155 to inhibit host defense. Frontiers in Immunology, 0, 13, .	4.8	3
511	Design principles to assemble drug combinations for effective tuberculosis therapy using interpretable pairwise drug response measurements. Cell Reports Medicine, 2022, 3, 100737.	6.5	16
512	Dormancy: There and Back Again. Molecular Biology, 2022, 56, 735-755.	1.3	2
513	Macrophage activation highlight an important role for NER proteins in the survival, latency and multiplication of Mycobacterium tuberculosis. Tuberculosis, 2023, 138, 102284.	1.9	3
514	An intelligent peptide recognizes and traps Mycobacterium tuberculosis to inhibit macrophage phagocytosis. Journal of Materials Chemistry B, 2022, 11, 180-187.	5.8	0
515	Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger. Microorganisms, 2022, 10, 2334.	3.6	6
516	Tuberculosis: The success tale of less explored dormant Mycobacterium tuberculosis. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	10
517	VapC toxin switches M. smegmatis cells into dormancy through 23S rRNA cleavage. Archives of Microbiology, 2023, 205, .	2.2	2

#	Article	IF	Citations
518	Discovery of Novel Transketolase Epitopes and the Development of IgG-Based Tuberculosis Serodiagnostics. Microbiology Spectrum, 2023, 11, .	3.0	3
519	A Structural View at Vaccine Development against M. tuberculosis. Cells, 2023, 12, 317.	4.1	7
520	Mouse Models for Mycobacterium tuberculosis Pathogenesis: Show and Do Not Tell. Pathogens, 2023, 12, 49.	2.8	3
521	Structural basis of the mycobacterial stress-response RNA polymerase auto-inhibition via oligomerization. Nature Communications, 2023, 14, .	12.8	2
522	Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics. Tuberculosis, 2023, 140, 102340.	1.9	5
523	Natural Metabolite Ursolic Acid as an Inhibitor of Dormancy Regulator DosR of Mycobacterium tuberculosis: Evidence from Molecular Docking, Molecular Dynamics Simulation and Free Energy Analysis. Current Computer-Aided Drug Design, 2023, 19, 425-437.	1.2	1
524	Shikimate Kinase Inhibitors: An Update on Promising Strategy against Mycobacterium tuberculosis. Current Drug Targets, 2023, 24, 388-405.	2.1	1
525	Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice. Npj Vaccines, 2023, 8, .	6.0	11
527	MicroRNAs as Biomarkers of Active Pulmonary TB Course. Microorganisms, 2023, 11, 626.	3.6	5
528	Chemoproteomic Approaches for Unraveling Prokaryotic Biology. Israel Journal of Chemistry, 2023, 63, .	2.3	2
529	Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. International Journal of Molecular Sciences, 2023, 24, 5202.	4.1	23
530	HIV/Mtb Co-Infection: From the Amplification of Disease Pathogenesis to an â€œEmerging Syndemicâ€• Microorganisms, 2023, 11, 853.	3.6	8
531	Mycobacterium tuberculosis CitA activity is modulated by cysteine oxidation and pyruvate binding. RSC Medicinal Chemistry, 0, , .	3.9	0
532	Multiomics Integration of Tuberculosis Pathogenesis. Integrated Science, 2023, , 937-967.	0.2	0
533	An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management. Pharmaceuticals, 2023, 16, 581.	3.8	8
534	Mycobacterium tuberculosis hijacks host TRIM21- and NCOA4-dependent ferritinophagy to enhance intracellular growth. Journal of Clinical Investigation, 2023, 133, .	8.2	7
535	A pro-oxidant property of vitamin C to overcome the burden of latent Mycobacterium tuberculosis infection: A cross-talk review with Fenton reaction. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0
536	Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes. Tuberculosis, 2023, , 102342.	1.9	1

#	Article	IF	Citations
537	Attenuated Cytokine-Induced Memory-Like Natural Killer Cell Responses to Mycobacterium tuberculosis in Tuberculosis Patients. Infection and Drug Resistance, 0, Volume 16, 2349-2364.	2.7	0
538	Revisiting the role of mesenchymal stem cells in tuberculosis and other infectious diseases. , 2023, 20, 600-612.		5
539	Eradication of Drug-Tolerant Mycobacterium tuberculosis 2022: Where We Stand. Microorganisms, 2023, 11, 1511.	3.6	0
540	Peptide microarray-based identification of dormancy-associated Mycobacterium tuberculosis antigens inducing immune responses among latent tuberculosis infection individuals in Thailand. Scientific Reports, 2023, 13, .	3.3	1
541	Mycobacterium tuberculosis Adaptation in Response to Isoniazid Treatment in a Multi-Stress System That Mimics the Host Environment. Antibiotics, 2023, 12, 852.	3.7	0
542	Structural insights into DarT toxin neutralization by cognate DarG antitoxin: ssDNA mimicry by DarG C-terminal domain keeps the DarT toxin inhibited. Structure, 2023, 31, 780-789.e4.	3.3	1
543	Long-acting vaccine delivery systems. Advanced Drug Delivery Reviews, 2023, 198, 114897.	13.7	6
544	Environmental, mechanistic and evolutionary landscape of antibiotic persistence. EMBO Reports, 2023, 24, .	4.5	3
545	The problem associated with tuberculosis in cattle and how this is being addressed. Revista Bionatura, 2023, 8, 1-9.	0.4	0
547	Repurposing of antibacterial compounds for suppression of Mycobacterium tuberculosis dormancy reactivation by targeting resuscitation-promoting factors B. Journal of Biomolecular Structure and Dynamics, 0, , 1-13.	3.5	1
548	Macrophage susceptibility to infection by Ghanaian Mycobacterium tuberculosis complex lineages 4 and 5 varies with self-reported ethnicity. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	1
549	Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and in vivo efficacy. Antimicrobial Agents and Chemotherapy, 0, , .	3.2	0
550	Horizontal Gene Transfer and Drug Resistance Involving Mycobacterium tuberculosis. Antibiotics, 2023, 12, 1367.	3.7	3
551	Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis. Microorganisms, 2023, 11, 2277.	3.6	6
552	The functional response of human monocyte-derived macrophages to serum amyloid A and Mycobacterium tuberculosis infection. Frontiers in Immunology, 0, 14, .	4.8	0
553	Inhaled drug delivery: Past, present, and future. Nano Today, 2023, 52, 101942.	11.9	3
554	Short-term effects of high-resolution (1-km) ambient PM2.5 and PM10 on hospital admission for pulmonary tuberculosis: a case-crossover study in Hainan, China. Frontiers in Public Health, 0, 11, .	2.7	0
555	Benzene Amide Ether Scaffold is Active against Non-replicating and Intracellular Mycobacterium tuberculosis. ACS Infectious Diseases, 2023, 9, 1981-1992.	3.8	0

#	Article	IF	Citations
557	The role of the host-microbiome and metabolomics in sarcoidosis. American Journal of Physiology - Cell Physiology, 0, , .	4.6	1
558	PathTracer Comprehensively Identifies Hypoxia-Induced Dormancy Adaptations in Mycobacterium tuberculosis. Journal of Chemical Information and Modeling, 2023, 63, 6156-6167.	5.4	0
559	Chitosan-based pulmonary particulate systems for anticancer and antiviral drug carriers: A promising delivery for COVID-19 vaccines. Results in Chemistry, 2023, 6, 101146.	2.0	0
560	Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis. International Journal of Molecular Sciences, 2023, 24, 14942.	4.1	0
562	Rv1255c, a dormancy-related transcriptional regulator of TetR family in Mycobacterium tuberculosis, enhances isoniazid tolerance in Mycobacterium smegmatis. Journal of Antibiotics, 0, , .	2.0	0
563	Detection of tuberculosis-associated compounds from human skin by GCxGC-TOFMS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2023, 1231, 123937.	2.3	0
564	Vaccine development against tuberculosis before and after Covid-19. Frontiers in Immunology, 0, 14, .	4.8	2
565	Tuberculosis diagnostic and treatment delays among patients in Uganda. Health Science Reports, 2023, 6, .	1.5	0
567	S288T mutation altering MmpL3 periplasmic domain channel and H-bond network: a novel dual drug resistance mechanism. Journal of Molecular Modeling, 2024, 30, .	1.8	0
568	Total hip Arthroplasty in Tubercular Hip Arthritis. , 2023, , 301-314.		0
569	Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains. Vaccine, 2024, 42, 1941-1952.	3.8	1
570	Initial nutrient condition determines the recovery speed of quiescent cells in fission yeast. Heliyon, 2024, 10, e26558.	3.2	0
571	Synthesis and In Vitro Antibacterial Evaluation of Mannich Base Nitrothiazole Derivatives. MolBank, 2024, 2024, M1793.	0.5	0